hexagons

Focused on rapidly developing cell therapies


Our global R&D network allows us to increase speed of clinical development

Legend Pipeline
hexagons

Legend Biotech remains fearless in our research

To accelerate the science and bring innovative therapies to patients, we will:


Enrich our pipeline
Advance our technology platforms
Commercialize our therapies

Program areas of development

Legend Biotech is utilizing the extensive cell therapy experience of our leadership and R&D staff, global clinical partners, and expanding research facilities to realize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors and infectious diseases.

image/svg+xmlALL, Acute lymphoblastic leukemia; BCMA, B - cell maturation antigen; DLBCL, diffuse large B - cell lymphoma; DLL3, delta - like ligand 3; GPC3, Glypican - 3; HCC, hepatoc ellular carcinoma; HIV, human immunodeficiency virus; IIT, investigator - initiated trial; NHL, non - Hodgkin lymphomas; MM, multiple myeloma; NSCLC, non small cell lung cancer; S CLC, small cell lung cancer; TCL, T - cell lymphoma *In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. Phase 1 IIT in China. Multiple allogeneic platforms are being developed. Infectious Diseases Solid Tumors TCL (CD4) NHL - DLBCL /ALL (CD19 x CD20 x CD22) MM* (BCMA) HIV (Undisclosed) LEGEND - 2 CARTITUDE - 4 Gastric (Claudin 18.2) Hematologic Malignancies CARTIFAN - 1 CARTITUDE - 2 Global China US HCC (GPC3) SCLC (DLL3) CARTITUDE - 1 Pancreatic (Claudin 18.2) MM (BCMA) Autologous CARTITUDE - 5 Allogeneic Preclinical Phase 1 Phase 2 Phase 3 CARTITUDE - 6 Autologous NSCLC (GPC3)

Rapid progress

Our milestones show our acceleration in product and infrastructure development


TIMELINE
2021

December: Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

September: Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

June: New data from the Phase 1b portion of CARTITUDE-1 Presented at ASCO

May: Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings

2020

May: Updated data from the Phase 1b portion of CARTITUDE-1 Presented at ASCO

May: Announced Collaborative Research and Licensing Agreement with Noile-Immune Biotech

2019

December: Initial result from the Phase 1b portion of CARTITUDE-1 presented at ASH 2019

December: JNJ-4528 granted Breakthrough Therapy Designation

May: Additional data from LEGEND-2 published in the Proceedings of the National Academy of Sciences of the United States of America

April: JNJ-4528 was granted the PRIME designation in the treatment of relapsed or refractory multiple myeloma

February: Joined other corporate industry leaders in the ASTCT Corporate Council

2018

December: Data from LEGEND-2 published in the Journal of Hematology & Oncology

December: Updated data from Phase 1/2 open-label study of LCAR-B38M (LEGEND-2) presented at ASH 2018

May: Phase 1b/2 IND for JNJ-4528 cleared by the FDA

March: Phase 2 IND for LCAR-B38M cleared by NMPA

2017

December: Worldwide collaboration and licensing agreement with Janssen signed in December

June: Results from an ongoing, early-phase clinical trial with LCAR-B38M presented at ASCO

2016

March: First RRMM patient treated with LCAR-B38M in China

2014

Legend Biotech business entity created



The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

*Ciltacabtagene autoleucel (cilta-cel) is an investigational B cell maturation antigen (BCMA) targeted chimeric antigen receptor T cell (CAR-T) therapy. It is being evaluated for the treatment of patients with multiple myeloma by regulatory authorities around the world.

We are rapidly advancing our 3 core cell therapy platforms:



CAR-T

CAR-T cells are genetically engineered T cells that express a chimeric antigen receptor (CAR), a hybrid protein containing three parts: a tandem antigen-binding domain of an antibody; a transmembrane domain; and the signal transduction elements of the T cell receptor complex.

The CAR antigen-binding domain seeks out tumor cells that express the target cell surface antigen.

Once the CAR finds its target, it sends out molecular signals via its intracellular modules to activate CAR-T cells, resulting in destruction of the target tumor cells.

Legend Biotech is actively developing cutting edge CAR-T therapies to address the unmet needs in oncology.

TCR-T

Legend Biotech recognizes that T-cell receptors (TCRs) isolated from tumor-specific T cells can be another effective approach to target tumors; in particular, solid tumors. Unlike CARs, TCRs can bind to polypeptides (antigens) derived from intracellular proteins.

Mutations with altered protein sequences occur frequently in many cancers. The mutated proteins are cleaved inside the cell and presented on the cell surface as polypeptides (epitopes) by the major histocompatibility complex (MHC). Neoepitopes are polypeptides derived from mutated genes/proteins presented only on tumors but not normal cells, which can be highly immunogenic and induce potent anti-tumor T-cell responses. TCRs isolated from neoepitope-specific T cells can then be engineered to TCR-T for clinical use.

At Legend Biotech, we are addressing the challenges of treating solid tumors by identifying novel TCRs to build TCR-T based on a foundation of studying with the leaders in the field, and further improving TCR-T as therapeutics by overcoming the immunosuppressive tumor microenvironment.

Allogeneic

Legend Biotech sees the promise of allogeneic cell therapy and its potential benefits. We are exploring a range of versatile tools and cell types in pursuit of a truly “off-the-shelf” cell therapy.

CAR-T

CAR-T cells are genetically engineered T cells that express a chimeric antigen receptor (CAR), a hybrid protein containing three parts: a tandem antigen-binding domain of an antibody; a transmembrane domain; and the signal transduction elements of the T cell receptor complex.

The CAR antigen-binding domain seeks out tumor cells that express the target cell surface antigen.

Once the CAR finds its target, it sends out molecular signals via its intracellular modules to activate CAR-T cells, resulting in destruction of the target tumor cells.

Legend Biotech is actively developing cutting edge CAR-T therapies to address the unmet needs in oncology.


TCR-T

Legend Biotech recognizes that T-cell receptors (TCRs) isolated from tumor-specific T cells can be another effective approach to target tumors; in particular, solid tumors. Unlike CARs, TCRs can bind to polypeptides (antigens) derived from intracellular proteins.

Mutations with altered protein sequences occur frequently in many cancers. The mutated proteins are cleaved inside the cell and presented on the cell surface as polypeptides (epitopes) by the major histocompatibility complex (MHC). Neoepitopes are polypeptides derived from mutated genes/proteins presented only on tumors but not normal cells, which can be highly immunogenic and induce potent anti-tumor T-cell responses. TCRs isolated from neoepitope-specific T cells can then be engineered to TCR-T for clinical use.

At Legend Biotech, we are addressing the challenges of treating solid tumors by identifying novel TCRs to build TCR-T based on a foundation of studying with the leaders in the field, and further improving TCR-T as therapeutics by overcoming the immunosuppressive tumor microenvironment.

Allogeneic

Legend Biotech sees the promise of allogeneic cell therapy and its potential benefits. We are exploring a range of versatile tools and cell types in pursuit of a truly “off-the-shelf” cell therapy.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

*Ciltacabtagene autoleucel (cilta-cel) is an investigational B cell maturation antigen (BCMA) targeted chimeric antigen receptor T cell (CAR-T) therapy. It is being evaluated for the treatment of patients with multiple myeloma by regulatory authorities around the world.

We seek to give patients new hope through tireless exploration and discovery, and we are just getting started.



Products approved in the United States:

Please see the U.S. full Prescribing Information, including BOXED WARNING and Medication Guide.

Visit carvyktirems.com

But we are just getting started!

You are about to leave LegendBiotech.com.
Are you sure you want to leave so soon?

Are you sure to reject all cookies?

User navigation to the site will be restricted.

Please Note: When NO option is selected, cookies are accepted automatically.